Filing Flows › Karyopharm Therapeutics (KPTI) › License and Other revenue
Karyopharm Therapeutics (KPTI) License and Other revenue by quarter
Karyopharm Therapeutics' License and Other revenue was $2.7M in Q2 2026 (second quarter 2026), -55% from Q1 2026. Over the last 7 quarters it ranged from $1.3M (Q4 2024) to $12.0M (Q3 2025).
| Quarter | License and Other revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.7M | -55% | -68% |
| Q1 2026 | $5.9M | +197% | -34% |
| Q4 2025 | $2.0M | -83% | +54% |
| Q3 2025 | $12.0M | +46% | — |
| Q2 2025 | $8.2M | -8% | — |
| Q1 2025 | $9.0M | +595% | — |
| Q4 2024 | $1.3M | — | — |
Q2 2026 at a glance
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Karyopharm Therapeutics' License and Other revenue?
Karyopharm Therapeutics' License and Other revenue was $2.7M in Q2 2026 (second quarter 2026), -55% from Q1 2026.
How has Karyopharm Therapeutics' License and Other revenue changed?
Over the last 7 quarters it ranged from $1.3M (Q4 2024) to $12.0M (Q3 2025).
Q2 2026 results → · How Karyopharm Therapeutics makes money →